xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

441

ICAR SINONASAL TUMORS

ized, phase III trial. Ann Oncol . 2023;34(3):251-261. https://doi.org/10.1016/j.annonc.2022.12.007 1711. Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol . 2018;19(10):1338-1350. https://doi. org/10.1016/S1470-2045(18)30495-9 1712. Lv JW, Li JY, Luo LN, Wang ZX, Chen YP. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials. J Immunother Cancer . 2019;7(1):159. https://doi.org/10.1186/ s40425-019-0636-7 1713. Mai HQ, Chen QY, Chen D. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopha ryngeal carcinoma: a multicenter randomized phase 3 trial. NatMed . 2021;27(9):1536-1543. 1714. Yang YP, Qu S, Li JA, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal car cinoma (CAPTAIN-1st): a multicentre, randomised, double blind, phase 3 trial. Lancet Oncol . 2021;22(8):1162-1174. https:// doi.org/10.1016/S1470-2045(21)00302-8 1715. Kuan EC, Alonso JE, Arshi A, St John MA. Nasopharyngeal adenocarcinoma: a population-based analysis. Am J Otolaryn gol . 2017;38(3):297-300. https://doi.org/10.1016/j.amjoto.2017. 01.028 1716. Wenig BM, Hyams VJ, Heffner DK. Nasopharyngeal papillary adenocarcinoma. A clinicopathologic study of a low-grade carcinoma. Am J Surg Pathol . 1988;12(12):946-953. 1717. Pineda-Daboin K, Neto A, Ochoa-Perez V, Luna MA. Nasopharyngeal adenocarcinomas: a clinicopathologic study of 44 cases including immunohistochemical features of 18 papillary phenotypes. Ann Diagn Pathol . 2006;10(4):215-221. https://doi.org/10.1016/j.anndiagpath.2005.11.002 1718. Carrizo F, Luna MA. Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases. Ann Diagn Pathol . 2005;9(4):189-192. https:// doi.org/10.1016/j.anndiagpath.2005.04.019 1719. Li L, Zhou F, Lin F, Han C. Clinicopathologic charac teristics of thyroid-like low-grade nasopharyngeal papil lary adenocarcinoma: a case report. Appl Immunohistochem Mol Morphol . 2019;27(8):e81-e84. https://doi.org/10.1097/PAI. 0000000000000545 1720. Wang X, Yan H, Luo Y, Fan T. Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the lit erature. Onco Targets Ther . 2016;9:2955-2959. https://doi.org/ 10.2147/OTT.S100447 1721. Huang F, Xiang X, Hong B, Min J, Li J. Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: a clinicopatho logic study of five cases and a literature review. Am J Clin Pathol . 2019;152(5):582-589. https://doi.org/10.1093/ajcp/ aqz082 1722. Lai Y, Li W, Zhai C, et al. Low-grade nasopharyngeal papillary adenocarcinoma: a review of 28 patients in a single institution. Cancer Manag Res . 2021;13:1271-1278. https://doi.org/10.2147/ CMAR.S288007 1723. Appukutty SJ, Di Palma S, Pitkin L, Smith CET. Thyroid-like low grade nasopharyngeal papillary

parallel-group, randomised, controlled, phase 3 trial. Lancet . 2021;398(10297):303-313. https://doi.org/10.1016/S0140 6736(21)01123-5 1699. Colevas AD, Yom SS, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr CancNetw . 2018;16(5):479-490. https://doi.org/10.6004/jnccn. 2018.0026 1700. Prawira A, Oosting SF, Chen TW, et al. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a system atic review. BrJCancer . 2017;117(12):1743-1752. https://doi.org/ 10.1038/bjc.2017.357 1701. Ma SX, Zhou T, Huang Y, et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal car cinoma: a systematic review and meta-analysis. Ann Transl Med . 2018;6(11):201. https://doi.org/10.21037/atm.2018.05.14 1702. Hong S, Zhang Y, Yu G. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall sur vival analysis of GEM20110714 phase III study. J Clin Oncol . 2021;39(29):3273-3282. 1703. Yang H, Lu Y, Xu ZH, Wei MJ, Huang HX. Gemcitabine plus platinum versus docetaxel plus platinum as first-line therapy for metastatic nasopharyngeal carcinoma: a randomized clin ical study. Saudi J Med Med Sci . 2021;9(2):125-134. https://doi. org/10.4103/sjmms.sjmms_471_20 1704. You R, Liu YP, Huang PY, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemother apy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol . 2020;6(9):1345-1352. https://doi.org/10.1001/jamaoncol. 2020.1808 1705. Wang G, Shen L. The efficacy of locoregional radiotherapy plus chemotherapy vs. chemotherapy alone in metastatic nasopharyngeal carcinoma: a meta-analysis. Ann Palliat Med . 2021;10(3):2584-2595. https://doi.org/10.21037/apm-20-1561 1706. Wang BC, Cao RB, Fu C, et al. The efficacy and safety of PD 1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta analysis. Oral Oncol . 2020;104(104640):104640. https://doi. org/10.1016/j.oraloncology.2020.104640 1707. Yang Y, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). J Immunother Cancer . 2021;9(12):e003790. https://doi.org/10. 1136/jitc-2021-003790 1708. Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carci noma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742). J Clin Oncol . 2018;36(14):1412 1418. https://doi.org/10.1200/JCO.2017.77.0388 1709. Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correla tive biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol . 2021;39(7):704-712. https:// doi.org/10.1200/JCO.20.02712 1710. Chan ATC, Lee VHF, Hong RL, et al. Pembrolizumab monotherapy versus chemotherapy in platinum pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, random